Medtronic received information through review of literature that in this cohort the patients were treated with flow-diversion devices, clinical mrs outcomes at discharge from the hospital were 0 for 12 patients, 1 for 41 patients, 2 for 3 patients, and 2 for 2 patients.During the post-procedure hospitalization, 4 patients developed procedure related ischemic events.One patient, with a giant aneurysm, developed a perianeurysmal brain inflammatory reaction in the fourth postprocedural week, which progressively resolved under steroids.One patient developed ischemic stroke at 3 months postintervention following discontinuation of clopidogrel without consulting the physician.Among the patients who had ischemic events or transient symptoms, 4 were treated with clopidogrel and 1, with a prasugrel regimen.There were reportedly 5 procedure-related morbidity.Periprocedural thrombus formation was encountered in 4.8% 3 of the cases; the latter was clinically evident as worsening of the clinical situation on awakening in 1 case and resulted in an increase of 2 points on the mrs score at discharge.In a 5-year period, 58 consecutive patients (17 men, 41 women; mean age, 52.4 years with 63 middle cerebral artery (mca) bifurcation aneurysms were included in this study.Fifty-seven aneurysms were treated with the pipeline embolization device and six were treated with a competitor¿s device.Most of the aneurysms were treated with single flow diversion (fd) coverage (58/63, 2 were covered in a telescopic fashion and there was adjunctive use of coils due to the large size for 3 aneurysms.In 3 other cases of single-fd coverage, the fd was deployed in a previously existing conventional intracranial stent.
|